Post-Marketing Patient Registries Conference

November 13-14, 2006
Chicago, IL

Event Overview

At the recent Patient Registries conference that took place November 13-14 in Chicago, IL, attendees were thrilled with the opportunity to network and share best practices from within the industry. Feedback focused around a quality conference agenda highlighting the variety of speakers, backgrounds and topics.

Sessions and Feedback Included:

Evolution of Patient Registries: Current Opportunities, Challenges and Future Directions
Nayan Nanavati
VP, Peri-Approval Clinical Research
PAREXEL

*Providing an excellent base for continued discussions throughout the conference program, Mr. Nanavati set the stage for a program filled with discussion and thought provoking conversations and dialogue among the conference attendees. His presentation focused on providing a comprehensive overview of the industry, exhibiting the many ways in which patient registries provide value to the life science industry.

Achieving Post-Marketing Commitments through Utilization of a Patient Registry
Richard Rudolph
VP Clinical & Medical Affairs
Cyberonics

*Dr. Rudolph's presentation focused on the benefits of utilizing a patient registry in completing post-marketing commitments mandated by regulatory authorities. As a Medical Device company, Cyberonics faces unique challenges in completing their trials, and the presentation brought to light several key strategies that can be applied by pharmaceutical companies.

Patient Registries as a Key Step to Quality Improvement and Measuring Effectiveness
Melva Covington, MPH, PhD
Manager, Global Health Outcomes
Product Phase Endocrine
Eli Lilly & Co.

*As one of the most highly rated presenters at this conference program, many individuals praised Dr. Covington's engaging speaking style, which truly kept the rapt attention of audience members. Her presentation provided an important viewpoint, in that quality improvement is one of the most importnat aspects of research studies.

Impact of Registries on Special Populations
W.David Dawson, PhD
Senior Director, Medical Affairs
ImClone Systems

*Dr. Dawson's presentation provided important information on the need and value of registries aimed at special populations. Several attendees noted his energetic speaking style and depth of knowledge on this subject.

Utilization of Patient Registries in Improving Overall Patient Quality of Life
Jack Johnson
Executive Director
Fabry Support & Information Group

*One of the most highly rated sessions at this conference program, Mr. Johnson's session provided an important and oft neglected topic among industry conferences, the perspective of the Patients. Coming from a leadership role for a patient advocacy group, this session highlighted the need for continued research and development and the impact on patients.

Pregnancy Registries
Charles Schwamlein, MD
Director, Global Surveillance & Pharmacoepidemiology
Abbott Laboratories

*The presentation delivered by Dr. Schwamlein addressed the various challenges and importance of maintaining pregnancy registries for various therapies. While the concept of pregnancy registries itself is not new, the perspective from Dr. Schwamlein provided strategic information for organizations wishing to build pregnancy registries.

Workshop: Achieving Multiple Goals in a Multi-Functional Registry
Presented by
Abt Associates, Inc.

*The workshop led by Abt Associates provided a tremendous amount of value to attendees based on the large amount of interaction and discussion that the presenters Neal Mantick, Masson Russel and Betsty Bogard fostered among the audience members. The topic was one of critical importance, as the need to achieve a variety of goals through the conduct of a registry is becoming increasingly important in validating the need for this type of research.

Use of Patient Registries in Ultra Orphan Populations
Betsy Bogard
Project Manager, Global Registry Programs
Genzyme

*Ms. Bogard's presentation on ultra orphan populations raised a variety of important considerations including the non-tangible value that can be derived from a patient registry serving a small population.

Pediatric Registries
AJ Allen, MD, PhD
Medical Director, Neuroscience Platform Team
Eli Lilly & Co.
Impact of Public Registries on Adverse Event Reporting
Jeff M. Trunzo
Vice President
Chesapeake Research Review, Inc.

If you attended this conference but were unable to update your flash drive with revised presentations, please email: Info@Q1Productions.com or Call: 312.822.8100.